Caliper Life Sciences launches COX-2 probe
Caliper Life Sciences has launched XenoLight RediJect COX-2 Probe (Fluorocoxibs), a fluorescent imaging agent for preclinical research that specifically detects the cyclooxygenase-2 (COX-2) biomarker noninvasively in live animal models as well as in ex vivo tissue analysis applications.

COX-2 detection in tumors has become an important tool in predicting the outcome of various chemotherapy treatments, including advanced lung cancer. Caliper's RediJect COX-2 probe provides the ability to non-invasively detect COX-2 in early stage cancer cells, said the Hopkinton, Mass.-based company.

The COX-2 fluorescent probe technology was invented at the research laboratory of Lawrence J. Marnett, PhD, director, Vanderbilt Institute of Chemical Biology at Vanderbilt University in Nashville, Tenn. and is licensed to Caliper.